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 Protective Intestinal Effects of Pituitary 
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 Abstract  Pituitary adenylate cyclase activating polypeptide (PACAP) is an 
endogenous neuropeptide widely distributed throughout the body, including the 
gastrointestinal tract. Several effects have been described in human and animal 
intestines. Among others, PACAP inﬂ uences secretion of intestinal glands, blood 
ﬂ ow, and smooth muscle contraction. PACAP is a well-known cytoprotective pep-
tide with strong anti-apoptotic, anti-inﬂ ammatory, and antioxidant effects. The 
present review gives an overview of the intestinal protective actions of this neuro-
peptide. Exogenous PACAP treatment was protective in a rat model of small bowel 
autotransplantation. Radioimmunoassay (RIA) analysis of the intestinal tissue 
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showed that endogenous PACAP levels gradually decreased with longer-lasting 
ischemic periods, prevented by PACAP addition. PACAP counteracted deleterious 
effects of ischemia on oxidative stress markers and cytokines. Another series of 
experiments investigated the role of endogenous PACAP in intestines in PACAP 
knockout (KO) mice. Warm ischemia–reperfusion injury and cold preservation mod-
els showed that the lack of PACAP caused a higher vulnerability against ischemic 
periods. Changes were more severe in PACAP KO mice at all examined time points. 
This ﬁ nding was supported by increased levels of oxidative stress markers and 
decreased expression of antioxidant molecules. PACAP was proven to be protective 
not only in ischemic but also in inﬂ ammatory bowel diseases. A recent study showed 
that PACAP treatment prolonged survival of  Toxoplasma gondii infected mice suf-
fering from acute ileitis and was able to reduce the ileal expression of proinﬂ amma-
tory cytokines. We completed the present review with recent clinical results obtained 
in patients suffering from inﬂ ammatory bowel diseases. It was found that PACAP 
levels were altered depending on the activity, type of the disease, and antibiotic 
therapy, suggesting its probable role in inﬂ ammatory events of the intestine. 
 Keywords  Ileitis •  Intestinal ischemia •  Crohn’s disease •  Colitis •  PACAP 
 Introduction 
 Pituitary adenylate cyclase activating polypeptide (PACAP) is a widely recognized 
neuroprotective peptide. The neuroprotective actions of PACAP were soon recog-
nized after its isolation from ovine hypothalami in 1989 [ 1 ,  2 ]. Subsequent studies 
showed that the occurrence of PACAP is widespread, it can be found in all organ 
systems, not only in the nervous system and so its general anti-apoptotic, anti-
oxidant, and anti-inﬂ ammatory effects can be observed in numerous different organs 
and tissues besides the nervous system. The neuroprotective and general cytopro-
tective effects of PACAP have been reviewed in the recent years, and several aspects 
of this action can be found in other chapters of this book [ 2 – 5 ]. 
 PACAP is also present in the gastrointestinal system where it exerts several 
actions. PACAP inﬂ uences motility of the intestinal wall [ 6 ], an action phyloge-
netically well conserved [ 7 ], and it also regulates sphincter muscles [ 8 – 10 ]. PACAP 
acts on intestinal secretion, among others, it has been shown that PACAP stimu-
lates secretion of growth factors, like brain-derived neurotrophic factor (BDNF) 
from intestinal smooth muscle cells [ 11 ]; furthermore, it inhibits pacemaker activ-
ity of interstitial cells of Cajal [ 12 ]. In the present review we brieﬂ y summarize 
protective actions of PACAP in the intestinal system, mainly in ischemic and 
inﬂ ammatory bowel disease models and give a brief summary of studies done in 
PACAP gene deﬁ cient mice. We also brieﬂ y review pathological ﬁ ndings on 
PACAP and/or receptor expression in both animal models and in human biopsies 
and we report on our recent ﬁ ndings in human samples from patients with inﬂ am-
matory bowel disease. 
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 Effects of Exogenous PACAP in Small Bowel 
Ischemia–Reperfusion Injury in Rats 
 Intestinal warm ischemia–reperfusion (I/R) is associated with high morbidity and 
mortality in some critical clinical settings, such as hemorrhagic shock, strangula-
tion, obstruction, cardiovascular surgery, and severe trauma. Several factors are 
involved in the cascade of events resulting in intestinal death and critical condition 
of the patient following mesenteric infarction. These include production of reactive 
oxygen species leading to oxidative stress, inﬂ ammation, and ﬁ nally tissue necrosis 
with septic signs [ 13 ,  14 ]. 
 PACAP has been shown to protect against ischemic injuries in several tissues. 
The ﬁ rst studies showing the neuroprotective effects of PACAP investigated these 
effects in global and focal brain ischemia [ 15 ,  16 ]. Subsequently, numerous other 
studies conﬁ rmed that PACAP exerts strong protective effects in neuronal ischemic 
injuries [ 2 ,  17 – 20 ]. PACAP’s efﬁ cacy in protecting tissues against ischemic lesions 
has become evident in the retina [ 21 – 23 ] and in peripheral tissues, such as liver 
[ 24 ], kidney [ 25 – 28 ], and heart [ 29 ]. Thus, it is not surprising that PACAP is also 
protective in intestinal I/R injury. In the following sections, we give a brief overview 
of our studies regarding the effects of exogenously administered PACAP in small 
intestinal ischemia, summarized in Fig.  17.1 .
 Our ﬁ rst studies showed that PACAP is protective in a rat model of small bowel 
autotransplantation, a cold ischemia injury model [ 30 – 32 ]. Small bowel was 
resected and grafts were preserved in University of Wisconsin solution, as commer-
cially available, standard solution during transplantation, with or without additional 
PACAP. Grafts were autotransplanted after 1, 2, 3, or 6 h with a reperfusion lasting 
3 h, a procedure called cold preservation injury. Radioimmunoassay (RIA) analysis 
of the intestinal tissue showed that endogenous PACAP levels gradually decreased 
with longer-lasting warm and cold ischemic periods, but tissue levels of both 
PACAP38 and PACAP27 remained higher when PACAP38 was added to the solu-
tion [ 30 ,  33 ]. Histological analysis showed that cold ischemia led to a destruction of 
the mucous, submucous, and muscularis layers, further deteriorated by the end of 
the reperfusion. PACAP protected the intestinal structure: a better preserved mucous 
layer and crypt morphology could be observed. These results clearly showed that 
PACAP was protective in intestinal cold I/R injury [ 30 ,  31 ]. They also demonstrated 
that adding PACAP to the preservation solution did not increase lipid peroxidation 
and prevented the reduction of endogenous scavenger capacity. 
 Studying the mechanism of action, we used biochemical assays to measure the 
oxidative stress markers and antioxidant enzyme levels, and molecular biological 
methods to study the expression of apoptotic signaling. Biochemical assays from the 
samples obtained after 3 h of reperfusion following 1, 2, 3, and 6 h of cold intestinal 
ischemia showed that malondialdehyde (MDA), an oxidative stress marker, gradually 
increased with the duration of the ischemia, while this increase was markedly less in 
the PACAP-treated groups. In contrast, levels of the endogenous scavenger molecule, 
reduced glutathione (GSH), showed a signiﬁ cant decrease with long-lasting I/R in the 
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control groups. In PACAP-treated groups, GSH levels were near baseline values and 
the level of this endogenous scavenger was higher in all PACAP-treated groups than 
in the ischemic control groups. A dramatic decrease was observed in activity of anti-
oxidant enzyme: superoxide dismutase (SOD) in the control ischemic groups. In 
PACAP-treated groups only a slight decrease could be observed. 
 In another study, we examined changes of cytokine expression in the intestinal 
tissue after different ischemic periods in University of Wisconsin solution with or 
without additional PACAP using cytokine array and Luminex multiplex immunoas-
say [ 33 ]. It was found that the cold ischemia-induced changes in some cytokines 
could be ameliorated by PACAP. Namely, elevations in expression level of the 
sICAM (CD54) and L-selectin (CD62L/LECAM-1) regulated upon activation could 
be decreased by PACAP treatment, similarly to a tendency observed in renal isch-
emic injury [ 25 ]. These adhesion molecules are known to be involved in crosstalk 
between immune cells and endothelial cells, and their overexpression can lead to 
microvascular dysfunction and reperfusion damage. PACAP led to a slight reduction 
 Fig. 17.1  Cytoprotective, anti-apoptotic, and anti-inﬂ ammatory effect of PACAP in intestinal 
warm ischemia–reperfusion (I/R) and transplantation (Tx)/cold ischemia animal models. Warm 
ischemia and cold storage in University of Wisconsin (UW) preservation solution lasted 1, 2, 3, or 
6 h, while reperfusion took 3 h in each groups. According to Park’s classiﬁ cation tissue injury was 
analyzed from grade zero (control) to the highest grade of injury (grade 5: G5). ( PACAP +/+ PACAP 
wild type mice,  PACAP −/− PACAP knockout mice,  MDA malondialdehyde,  GSH reduced glutathi-
one,  SOD superoxide dismutase,  pERK1/2 phosphorylated-ERK1/2,  pJNK phosphorylated-Jun-N- 
terminal kinase,  p38 MAPK p38 Mitogen Activated Protein Kinase,  sICAM1 soluble Intercellular 
Adhesion Molecule-1,  TIMP-1 Tissue Inhibitor of MetalloProteinase-1) 
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also in RANTES levels and a signiﬁ cant decrease of the strongly induced TIMP 
levels [ 33 ]. Studying the mitogen activated protein (MAP) kinase phosphorylation, 
we found that phosphorylated ERK1/2 levels gradually decreased with the ischemic 
time, while JNK1/2 and p38 MAP kinase phosphorylation increased. These changes 
were counteracted by addition of PACAP in the preservation solution [ 32 ]. 
 Altogether, these studies showed that PACAP is protective in intestinal I/R injury 
partly through increasing the antioxidant status of the intestinal tissue, via anti- 
inﬂ ammatory actions and via anti-apoptotic signaling. This combination of anti- 
apoptotic, anti-oxidant, and anti-inﬂ ammatory actions of PACAP have been conﬁ rmed 
by several other studies. One of the best-known protective effects of PACAP is its 
anti-apoptotic effect [ 34 ], which has been extensively studied in the nervous system 
[ 35 – 37 ], sensory organs like inner ear [ 38 ] and retina [ 39 ] and has also been shown in 
peripheral organ lesions, such as in diabetic nephropathy [ 40 ], and in oxidative stress-
induced cardiomyocyte injury [ 41 ,  42 ]. 
 The antioxidant efﬁ cacy of PACAP has also been described in other studies. 
Miyamoto et al. [ 43 ] showed that PACAP suppressed cortical damage in mice with 
traumatic brain injury by enhancing antioxidant activity. In diabetic nephropathy, 
Banki et al. [ 40 ] showed that PACAP treatment increased glutathione levels. PACAP 
also stimulated glutathione formation, and blocked H 2 O 2 -evoked reactive oxygen 
species (ROS) accumulation and glutathione content reduction in oxidative stress- 
induced astroglial injury [ 44 ]. In kidney ischemia–reperfusion, similar changes were 
observed: PACAP treatment decreased MDA levels while increased GSH levels [ 45 ]. 
These studies suggest that PACAP has anti-oxidant effects via indirect action of 
mechanism, through stimulating endogenous antioxidant capacity. This hypothesis 
is also supported by the observation that direct scavenging action of PACAP can only 
be observed at very high (micromolar) concentrations of the peptide [ 46 ]. 
 The anti-inﬂ ammatory actions of PACAP have been more widely investigated. It 
has been shown that the anti-inﬂ ammatory effects of the peptide are partially medi-
ated via suppressing chemokine/cytokine production [ 47 ]. PACAP plays an impor-
tant regulatory role in the immune system, a function reviewed several times by 
different groups [ 48 ,  49 ]. The role of PACAP in cytokine and chemokine expression 
has been investigated in the nervous system as well as in peripheral organs. 
Microglial cytokine and chemokine expression was shown to be altered by PACAP 
resulting in a neuroregeneration-favoring environment [ 50 – 52 ]. In the retina, 
PACAP increased anti-inﬂ ammatory cytokine expression [ 53 ]. Furthermore, 
PACAP led to an anti-inﬂ ammatory cytokine balance in kidney ischemia [ 25 ], in 
diabetic nephropathy model [ 54 ] and in retinal ischemia [ 55 ]. 
 Small Intestinal Ischemic Injury in PACAP 
Knockout (KO) Mice 
 To answer the question of whether the intestinal protective action of PACAP can also 
be observed endogenously, we studied the results of intestinal I/R in PACAP KO 
mice, summarized in Fig.  17.1 [ 56 – 58 ]. No difference in the histological structure 
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between young wild type and PACAP KO mice (heterozygous or homozygous) 
could be observed under normal circumstances (Fig.  17.2 ). However, in ischemic 
injuries, PACAP KO mice showed a higher degree of tissue injury. Cold preservation 
injury was studied by removing small bowel from wild type and PACAP KO mice 
and placing them in University of Wisconsin preservation solution for 1, 3 and 6 h. 
Small bowel biopsies were collected after the ischemic periods and after laparotomy 
for controls. We investigated the histological structure as well as the above- mentioned 
oxidative stress parameters. Most severe injury was observed after 6 h of cold stor-
age, as expected. After 1 h of cold preservation, only minor clefting with the villus 
epithelium adjacent to the crypts left intact. Changes were more severe in PACAP 
KO mice at all examined time points. After 6 h, severely injured crypt appeared with 
denuded villi corresponding to most severe tissue injury (Grade 4), while in wild 
type mice this was less severe, Grade 3 injury. Quantitative histological analysis also 
conﬁ rmed this observation: mucosal thickness showed a more severe decrease with 
more prolonged ischemic times, and this decrease was more severe in PACAP KO 
mice. Similarly, depth of crypts and submucosal thickness were also more severely 
affected in PACAP-deﬁ cient mice. Measuring the parameters of oxidative stress 
revealed that the increase of MDA was higher, while the decrease in GSH and SOD 
was more pronounced in PACAP KO mice, indicating an elevated oxidative stress 
level in mice lacking endogenous PACAP. This corresponds well with the increased 
tissue injury revealed by the histological analysis [ 56 ].
 We also performed warm ischemic injury in PACAP KO mice [ 57 ]. Warm isch-
emia was induced by occlusion of the superior mesenteric artery for 1, 3 or 6 h. 
Similarly to the above studies, histological and biochemical analyses were per-
formed. Histology showed that PACAP KO mice suffered a more severe tissue 
injury at all time points. For example, 3 h of ischemia resulted in severely injured 
crypts and denuded villi in KO mice, while this histological picture was character-
istic in the wild type group only after 6 h of ischemic time (Fig.  17.2 ). Quantitative 
histological analysis conﬁ rmed these observations: both mucosal and submucosal 
thickness as well as crypt depth were more severely decreased in mice lacking 
endogenous PACAP. Studying the oxidative stress markers, results similar to those 
observed in cold ischemic injury were obtained: levels of MDA were more signiﬁ -
cantly increased in the KO groups, while those of the antioxidant SOD and GSH 
were more severely decreased than in the wild type animals ([ 57 ], Fig.  17.1 ). 
 These results are in agreement with the general observation that PACAP KO mice 
are more vulnerable to tissue injuries than wild type mice [ 59 ]. This is also true for 
ischemic injuries. Ohtaki and coworkers showed that PACAP KO mice have 
increased infarct volume in a model of stroke [ 60 ] with increased edema formation 
[ 61 ]. Similar results were obtained in the retina: in bilateral carotid artery occlusion- 
induced retinal ischemia PACAP KO mice showed increased tissue damage [ 62 ]. In 
peripheral organ ischemia, it has been shown that PACAP KO mice react with 
increased tissue injury in ischemia–reperfusion-induced kidney lesion [ 27 ,  63 ]. 
Increased inﬂ ammatory response has also been demonstrated in endotoxin-induced 
lung injury [ 64 ] and in contact dermatitis [ 65 ]. In the background of this increased 
susceptibility, a decrease in the endogenous reserve capacity, to withstand the tissue 
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damaging effect of different harmful stimuli, is suggested. Some studies have 
already sought to elucidate detailed mechanisms. A proteomic analysis of PACAP 
KO mice showed that several altered proteins are involved in metabolic processes, 
energy homeostasis, and structural integrity [ 66 ]. ATP-synthase and tubulin beta- 2A 
 Fig. 17.2  Representative photomicrographs of small bowel sections from young adult PACAP +/+ , 
PACAP +/− , and PACAP −/− mice. Tissue injury of small bowel after 3 and 6 h warm I/R and 3 h and 
6 h cold preservation in UW in PACAP +/+ and in PACAP −/− mice (Hematoxylin and eosin staining). 
 PACAP +/+ : PACAP wild type mice,  PACAP −/− : PACAP knockout mice,  PACAP +/− : PACAP hetero-
zygous mice 
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were expressed more strongly in PACAP KO mice. In contrast, the expression of 
more peptides/proteins markedly decreased in KO mice, like pyruvate kinase, fructose 
biphosphate aldolase-A, glutathione S-transferase, peptidyl propyl cis-trans isomer-
ase-A, gamma enolase, and aspartate amino transferase. The altered expression of 
these enzymes might partially account for the decreased antioxidant and detoxifying 
capacity of PACAP-deﬁ cient mice accompanying the increased vulnerability of these 
animals [ 66 ]. Increased proinﬂ ammatory status of neurons has also been reported in 
the background of increased vulnerability of PACAP KO mice [ 67 ]. 
 Effects of PACAP in Small Intestinal Infl ammation 
 Inﬂ ammatory bowel disease (IBD) comprises two major clinically deﬁ ned types: 
Crohn’s disease (CD) and ulcerative colitis (UC). Crohn’s disease generally affects 
the ileum and colon, but can be present in any region of gastrointestinal tract, while 
ulcerative colitis is only conﬁ ned to colon and rectum. Crohn’s disease is often 
transmural and can be associated with granulomas, strictures and ﬁ stulas. On the 
contrary, ulcerative colitis mostly affects the mucous membrane [ 68 ]. In the next 
sections we discuss ﬁ ndings in small and large intestinal inﬂ ammation animal mod-
els and human diseases. 
 The occurrence and different effects of PACAP in the small intestine have been 
described in several species [ 69 – 73 ]. Regarding pathological conditions, it has been 
described that in atrophic rat ileum neurons expressing VIP and PACAP decrease in 
number [ 69 ]. Subsequent studies showed that intestinal adaptation after bypassing 
the distal ileum of the rat includes a transient supersensitivity of the longitudinal 
muscle to VIP and PACAP-27, and these augmented relaxatory responses may con-
tribute to the hypomotility noted in inactive intestine [ 69 ]. In humans, Belai et al. 
[ 74 ] studied PACAP immunohistological expression in patients with Crohn’s dis-
ease. They investigated the neurochemical composition of the neurons and nerve 
ﬁ bers of the myenteric plexus, circular smooth muscle and serosa layer of the ileal 
wall from nine patients with Crohn’s disease and compared it with seven samples 
from normal controls. Increased PACAP immunoreactivity along with increased 
VIP and NO synthase was seen in the myenteric plexus and nerve ﬁ bers of the cir-
cular muscle layer, in the afﬂ icted segment of Crohn’s ileum. Another study on 
human small intestine reported a decrease of PACAP immunoreactivity along with 
loss of interstitial cells of Cajal in diabetic gastroenteropathy [ 75 ]. 
 In our recent study applying a  Toxoplasma gondii -induced acute ileitis model, 
mice were treated with PACAP38 once daily via the intraperitoneal route in two 
different regimens; namely, between days 1–6 postinfection (as prophylaxis) or 
starting on day 4 (till day 6, as therapeutic treatment), when ﬁ rst histopathological 
changes are observed in the ileal mucosa [ 76 ]. The treatment prolonged the survival 
of the infected mice: while all placebo-treated control mice died by day 9.5, 80 % of 
mice with PACAP prophylaxis and 40 % with PACAP therapeutic treatment sur-
vived the acute phase. Twenty percent of the prophylaxis group survived till the end 
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of experiment. This inﬂ ammation ameliorating (anti-inﬂ ammatory) effect of 
PACAP was further supported by less pronounced weight loss of treated mice, and 
by less distinct shrinkage of the small intestines. Histopathological examination of 
the ileal mucosa revealed that 7 days postinfection, placebo-treated control mice 
displayed severe necrosis of the mucous membrane, whereas moderate ileitis was 
found in the PACAP therapeutic group and only mild inﬂ ammation in the prophy-
laxis group. Given that PACAP did not exert direct effects on the intestinal micro-
biota composition, the beneﬁ cial effects are rather due to the anti-inﬂ ammatory, 
protective actions of the peptide as conﬁ rmed by studies of deﬁ ned pro- and anti- 
inﬂ ammatory markers. The local increase in CD3+ T cells, for instance, and the 
local decrease in regulatory T cells was less marked in the PACAP-treated groups. 
In addition, lower ileal neutrophils, monocytes and macrophages were observed 
after PACAP treatment. Furthermore, ileal expression of proinﬂ ammatory cytokines 
including IL-23p19 (interleukin- 23p19), IL-22 (interleukin-22), IFN-gamma 
(interferon gamma), and MCP-1 (monocyte chemoattractant protein-1) was reduced 
in ileal ex vivo biopsies derived from PACAP-treated mice. The diminished pro- 
inﬂ ammatory response upon PACAP was further underlined by lower protein con-
centrations of IFN-gamma and NO in ex vivo biopsies of mesenteric lymph nodes 
taken from PACAP-treated mice. Our results from extraintestinal compartments 
revealed that PACAP prophylaxis also abrogated systemic inﬂ ammatory responses, 
as demonstrated by the decreased level of TNF-alpha (tumor necrosis factor alpha) 
and NO (nitrogen monoxide) in the spleen and of TNF-alpha, IFN-gamma, MCP-1, 
and IL-6 (interleukin-6) in the liver. Higher levels of anti-inﬂ ammatory cytokines 
such as IL-10 and IL-4 were measured in the serum/spleen and in the liver/mesen-
teric lymph node, respectively, of PACAP-treated animals. Furthermore, kidney and 
lung histology revealed less tissue damage after PACAP prophylaxis. Altogether, 
these results show that both PACAP therapeutic and prophylactic treatments can 
reduce the symptoms and pathological signs of ileitis in a murine model by a com-
plex mechanistic network. The prophylactic treatment resulted to be more effective 
(in a time-of-treatment dependent manner), and could also reduce the extraintestinal 
sequelae of the  T. gondii induced inﬂ ammation [ 76 ]. 
 Effects of PACAP in Large Intestinal Infl ammation 
 Similarly to the small intestine, occurrence of PACAP and its receptors as well as 
different functions of PACAP have been described in the large intestine of different 
species, including humans [ 77 – 82 ]. Regarding pathological changes, only a few 
data are available. Gonkowski and Calka [ 81 ] reported that immunoreactive PACAP 
changes in different large intestinal pathologies in the pig. They found that in the por-
cine descending colon chemically induced inﬂ ammation, nerve injury, and prolifer-
ative enteropathy (a naturally occurring inﬂ ammation of the porcine digestive tract) 
resulted in an increase in the number of PACAP-27-like immunoreactive (LI) nerve 
ﬁ bers in the circular muscle and mucosal layers. The number of PACAP-containing 
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perikarya also increased in all cases in the myenteric and submucosal plexus, except 
for the outer submucosal plexus in case of axotomy-induced pathology. In another 
study, Wojtkiewicz et al. [ 83 ] described inﬂ ammation-induced changes in the neu-
rochemical composition of the inferior mesenteric ganglia supplying the lower por-
tion of the colon in pigs. Although PACAP was not investigated, they found that 
the number of VIP immunoreactive neurons was reduced in proliferative enteropa-
thy. Changes in PACAP and receptor expression were also demonstrated in dextran 
sodium sulfate (DSS)-induced colitis of mice. A marked upregulation of PACAP 
(and of VIP) mRNA expression was shown in TRPA1 (transient receptor potential 
Ankyrin type 1) KO mice, while this was not observed in wild type controls [ 84 ]. 
Expression levels of VPAC2 and PAC1R mRNA were not altered, whereas that of 
VPAC1 was downregulated in TRPA1 KO mice 10 days following colitis induction 
[ 84 ]. An earlier study revealed that mice lacking the TRPV-1 (transient receptor 
potential cation channel subfamily V member 1) receptor exhibit a defect in PACAP 
expression. The authors argue that this might contribute to the development of a 
local pro- inﬂ ammatory environment characteristic for these mice. This might also 
be an additional factor for colitis-associated cancer development [ 85 ]. 
 Regarding human colonic samples, in an earlier study we found signiﬁ cantly lower 
levels of PACAP38-LI and PACAP27-LI in tumoral and peripheral samples compared 
with normal healthy tissue in colon cancers, similarly to some urogenital tumors [ 86 , 
 87 ]. This observation is in accordance with immunohistochemical analysis of human 
sigmoid colon and rectum tumors, where a less dense PACAP immunoreactive nerve 
ﬁ ber network was observed in the myenteric and submucosal plexi than in normal con-
trols [ 88 ]. Another study found that in patients with symptomatic diverticular disease 
signiﬁ cantly higher PACAP levels can be detected along with increases in other neuro-
peptides within the mucosal plexus. Patients with symptomatic diverticular disease 
exhibit increased neuropeptides in mucosal biopsies, which may reﬂ ect resolved prior 
inﬂ ammation, as it parallels the changes seen in acute and chronic diverticulitis [ 89 ]. In 
contrast, another study found decreased density of PACAP containing nerve ﬁ bers in 
colon mucosal membrane of children with ulcerative colitis [ 90 ,  91 ]. Decreased immu-
noreactivity (measured both by  immunohistochemistry and RIA) was also observed in 
the aganglionic segment of human colon with Hirschsprung’s disease [ 92 ]. 
 Measurement of PACAP Levels in Human Infl ammatory 
Bowel Diseases 
 Our group performed a human study to determine PACAP levels in inﬂ ammatory 
conditions. We examined samples taken from patients suffering from ulcerative colitis 
( n = 30) or Crohn’s disease ( n = 22) and used samples obtained from patients having 
diarrhea without any morphological abnormality as controls ( n = 8), after obtaining 
patients’ consent. In both groups of IBD 3 grades were distinguished: (1) chronic 
inﬂ ammation with lymphocyte and plasma cell inﬁ ltration without cryptitis or crypt 
abscess; (2) acute inﬂ ammation with cryptitis or crypt abscess and neutrophil 
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inﬁ ltration; (3) normal mucous membrane showing no signs of inﬂ ammation. For 
observing the effects of antibiotic therapy on PACAP level, colon samples of IBD 
patients treated with metronidazol or ciproﬂ oxacin/metronidazol combination (CD: 
 n = 5; UC:  n = 7) were also examined. The procedure used was in accordance with 
protocols approved by the ethical committee (no. 2784,3117, University of Pecs; 
8-28/92 009-10 I 8EKU, ETT TUKEB, Ministry of Health, Hungary). Tissue samples 
were weighed and homogenized in ice-cold distilled water. The homogenate was cen-
trifuged (12,000 rpm, 4 °C, 30 min), and the supernatant was further processed for 
RIA analysis of PACAP38 and PACAP27 contents, as previously described [ 93 ,  94 ]. 
For these measurements antiserum PACAP38 “88111-3” (working dilution, 1:10,000) 
and PACAP27 “88123” (dilution: 1:45,000) were used. 
 These results show marked increase in both PACAPs’ levels in ulcerative colitis 
(Fig.  17.3 ), but only a slight increase in PACAP38 could be detected in Crohn’s dis-
ease (Fig.  17.4 ) compared to normal mucous membrane of these patients showing no 
inﬂ ammatory signs. We found that both PACAP38 and PACAP27 levels of normal 
mucous membrane samples of UC patients were much lower than in the inﬂ amed 
samples, but there were no differences in case of CD patients. Measuring PACAP 
levels, signiﬁ cant elevation of both PACAPs could be detected in samples obtained 
from colon of UC patients showing acute inﬂ ammation. Studying the possible effect 
of antibiotics on PACAP levels in IBD patients revealed a signiﬁ cant decrease of both 
PACAP38 and PACAP27 level in UC patients receiving antibiotics treatment 
(Fig.  17.5 ). A moderate, but detectable decrease of PACAPs was seen in samples of 
CD patients.
 Effects of Endogenous PACAP 
 The protective effects of endogenous PACAP have also been shown in mouse mod-
els of inﬂ ammatory colon diseases performed in PACAP KO mice [ 59 ]. Two groups, 
independently of each other and at the same time, reported similar results in DSS- 
induced colonic inﬂ ammation, a model of inﬂ ammatory bowel disease [ 95 ,  96 ]. 
 Fig. 17.3  PACAP38-like immunoreactivity (LI) and PACAP27-LI as measured by RIA in colon 
samples from patients suffering from ulcerative colitis. Data are expressed as mean fmol/mg tissue 
weight ± SEM. ** p < 0.01; *** p < 0.001 
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Azuma and coworkers [ 95 ], using a 7-day exposure (short-term) to DSS, found that 
PACAP KO mice exhibited higher mortality (increased by about 50 %) and increased 
weight loss, bleeding and diarrhea, symptoms that are used to determine the disease 
activity index. The large intestines were more shortened in PACAP KO mice, to one 
third of wild type mice. Similarly to our observations, the authors did not ﬁ nd mor-
phological differences in the colonic sections in intact PACAP KO mice. However, 
histological scoring of the proximal and distal colon parts in DSS-induced colitis 
showed an increased number of inﬁ ltrating cells and crypt damage in PACAP- 
deﬁ cient mice. Furthermore, production of IL-1beta and IL-6 was upregulated by 
50 % in the proximal colon of PACAP-deﬁ cient mice, and that of IFN-gamma, 
IL-1beta, IL-6, IL-12, and keratinocyte-derived chemokine expression was upregu-
lated in the distal colon by 50 % [ 95 ]. Conversely, levels of anti-inﬂ ammatory cyto-
kines such as IL-10 were only one third of that of wild type mice in the distal colon. 
Using a longer exposure to DSS (2 months), Nemetz and coworkers [ 96 ] described 
similar results. After induction of colitis by exposure to DSS, PACAP knockout 
animals displayed more severe clinical symptoms and higher histological inﬂ amma-
tion scores (50–70 % higher), restricted to the distal colon. In addition, induction of 
IL-1beta and IL-6 mRNA expression levels were signiﬁ cantly higher (70 %) in 
PACAP-deﬁ cient mice. Interestingly, 60 % of PACAP KO mice developed colorec-
tal tumors with aggressive-appearing pathology [ 96 ]. 
 Fig. 17.4  PACAP38-LI and PACAP27-LI as measured by RIA in colon samples from patients 
suffering from Crohn’s disease. Data are expressed as mean fmol/mg tissue weight ± SEM 
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 As both studies showed, PACAP-deﬁ cient mice receiving normal water without 
DSS displayed no signs of inﬂ ammation (and of colitis), suggesting that the lack of 
endogenous PACAP does not result in immune depression leading to spontaneous 
development of colitis. This is in agreement with our own observations that mice 
lacking endogenous PACAP do not spontaneously develop increased inﬂ ammatory 
status (not shown), but based on the above-described reports, the lack of endoge-
nous PACAP leads to increased vulnerability to inﬂ ammation and inﬂ ammation- 
associated cancer development in the colon. 
 In summary, PACAP is widely distributed in the gastrointestinal tract and exerts 
several different effects. Based on the studies reviewed here in detail, PACAP seems 
to be an important endogenous protective factor in ischemic and inﬂ ammatory bowel 
diseases and exogenous PACAP treatment can counteract changes in ischemic and 
inﬂ ammatory models. Human data indicate that PACAP levels change in inﬂ amma-
tory conditions the clinical relevance of which needs further investigation. 
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